The European Medicines Board elects Christa Wirthumer-Hoche as chair of their Management Board.
On March 17, 2016, the European Medicines Agency (EMA) announced the election of Christa Wirthumer-Hoche as chair of the agency’s Management Board for a three-year period. The announcement was made at the board’s meeting in London. The Management Board sets EMA’s budget, approves the annual work program, and overseas the agency’s collaborative work with partner organizations across the EU and beyond.
Wirthumer-Hoche, currently the head of the Austrian Medicines and Medical Devices Agency, has served as the vice-chair of the EMA Management Board since March 2015 and has been a member of the board since October 2013. She is co-chair of the EU Network Training Centre and has previously served as chair of EMA’s Active Substance Master File Working Group.
“It is a great honor to be appointed as chair of EMA’s Management Board,” said Wirthumer-Hoche at the March 17 board meeting, EMA reported in a press release. “As chair, my ambition is to ensure a strong partnership between EMA, the European Union national competent authorities, and the European Commission to guarantee that EMA is able to fulfill its important role of safeguarding human and animal health in Europe.”
EMA’s Executive Director, Guido Rasi, said in a press release, “I am delighted to welcome Dr Wirthumer-Hoche as the new chair of the agency’s Management Board. As vice-chair of the board, she has already demonstrated many times that she has the vision and leadership ability required for this important role. I look forward to our close collaboration.”
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.